News and Comments

ARCA BIOPHARMA: A GENETICALLY TARGETED DRUG FOR ATRIAL FIBRILLATION IN HEART FAILURE PATIENTS

  Thursday, January 09, 2014

A Colorado-based biopharmaceutical company, ARCA Biopharma (ABIO) has a genetically-targeted drug, GencaroTM (bucindolol hydrochloride), for Atrial fibrillation (AF) in patients with heart failure (HF). The drug offers a personalized medicine approach for the treatment of AF in HF, treating only individuals with certain genetic characteristics. This approach enables the selection of individuals who would most probably respond to the drug through excluding the expected non-responders, thus reducing statistically failed trial outcome, in addition to decreasing clinical trial and healthcare costs.    More...


Recent News_and_Comments


Archive


Tags